CML: Initiating, Switching, and Monitoring Therapy

December 31, 2009

This Webcast activity concerns the various aspects of managing therapy for patients with CML.

Credits: 1.50

Fee: None

Expires: October 30, 2010

Multimedia: Webcast

This Webcast activity concerns the various aspects of managing therapy for patients with CML. After completing the activity, oncology nurses should be able to review the safety and efficacy of tyrosine kinase inhibitors in treating patients with CML based on results from recent clinical trials, discuss disease monitoring to determine treatment response and when switching therapy is necessary, describe the standard of care in first-line therapy and ongoing investigational trials in patients initiating therapy, and outline a treatment plan for the management of patients with advanced-phase CML and imatinib resistant/intolerant CML.

Click here to access this third-party website.